Spinal Laminectomy Post-Op [1810]

General	
Common Present on Admission Diagnosis	
Acidosis	Post-op
Acute Post-Hemorrhagic Anemia	Post-op
Acute Renal Failure	Post-op
Acute Respiratory Failure	Post-op
Acute Thromboembolism of Deep Veins of Lower	Post-op
Extremities	•
Anemia	Post-op
Bacteremia	Post-op
Bipolar disorder, unspecified	Post-op
Cardiac Arrest	Post-op
Cardiac Dysrhythmia	Post-op
Cardiogenic Shock	Post-op
Decubitus Ulcer	Post-op
Dementia in Conditions Classified Elsewhere	Post-op
Disorder of Liver	Post-op
Electrolyte and Fluid Disorder	Post-op
Intestinal Infection due to Clostridium Difficile	Post-op
Methicillin Resistant Staphylococcus Aureus Infection	Post-op
Obstructive Chronic Bronchitis with Exacerbation	Post-op
Other Alteration of Consciousness	Post-op
Other and Unspecified Coagulation Defects	Post-op
Other Pulmonary Embolism and Infarction	Post-op
Phlebitis and Thrombophlebitis	Post-op
Protein-calorie Malnutrition	Post-op
-	
Psychosis, unspecified psychosis type Schizophrenia Disorder	Post-op
· · · · · · · · · · · · · · · · · · ·	Post-op
Sepsis Sepsis	Post-op
Septic Shock	Post-op
Septicemia Signatura Signatura Military in	Post-op
Type II or Unspecified Type Diabetes Mellitus with Mention of Complication, Not Stated as Uncontrolled	Post-op
Urinary Tract Infection, Site Not Specified	Post-op
lective Outpatient, Observation, or Admission (Single	Response)
Elective outpatient procedure: Discharge following routine recovery	Routine, Continuous, PACU & Post-op
Outpatient observation services under general	Diagnosis:
supervision	Admitting Physician:
	Patient Condition:
	Bed request comments:
	PACU & Post-op
Outpatient in a bed - extended recovery	Diagnosis:
	Admitting Physician:
	Bed request comments:
	PACU & Post-op
Admit to Inpatient	Diagnosis:
	Admitting Physician:
	Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgme
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights. PACU & Post-op
	•
nted on 9/17/2020 at 8:35 AM from SUP	Page 1 c

Admission	or Observation	ı (Single	Respons	se)
Patient ha	as active outpat	ient status	s order o	n file

() Admit to Inpatient	Diagnosis: Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights.
() Outpatient observation services under general supervision	PACU & Post-op Diagnosis: Admitting Physician: Patient Condition: Bed request comments:
() Outpatient in a bed - extended recovery	PACU & Post-op Diagnosis:
`	Admitting Physician: Bed request comments: PACU & Post-op
() Transfer patient	Level of Care: Bed request comments: Scheduling/ADT
Return to previous bed Admission (Single Response) Patient has active status order on file	Routine, Until discontinued, Starting S, Scheduling/ADT
() Admit to inpatient	Diagnosis: Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op
() Transfer patient	Level of Care: Bed request comments: Scheduling/ADT
() Return to previous bed Transfer (Single Response) Patient has active inpatient status order on file	Routine, Until discontinued, Starting S, Scheduling/ADT
() Transfer patient	Level of Care: Bed request comments: Scheduling/ADT
() Return to previous bed	Routine, Until discontinued, Starting S, Scheduling/ADT
Code Status	
[] Full code	Code Status decision reached by: Post-op
[] DNR (Do Not Resuscitate) (Selection Required) [] DNR (Do Not Resuscitate) Do	pes patient have decision-making capacity?

[] Consult to Palliative Care Service	Priority: Reason for Consult? Order? Name of referring provider: Enter call back number:
[] Consult to Social Work	Reason for Consult: Post-op
[] Modified Code	Does patient have decision-making capacity? Modified Code restrictions: Post-op
[] Treatment Restrictions	Treatment Restriction decision reached by: Specify Treatment Restrictions: Post-op
Isolation	
[] Airborne isolation status	
[] Airborne isolation status	Details
 Mycobacterium tuberculosis by PCR - If you suspect Tuberculosis, please order this test for rapid diagnostics. 	Once, Sputum, Post-op
[] Contact isolation status	Details
Droplet isolation status	Details
[] Enteric isolation status	Details
Precautions	
[] Aspiration precautions	PACU & Post-op
[X] Fall precautions	Increased observation level needed:
	PACU & Post-op
[] Latex precautions	PACU & Post-op
[] Seizure precautions	Increased observation level needed: PACU & Post-op
[] Spinal precautions	PACU & Post-op
Nursing	
Vital Signs (Single Response)	
(X) Vital signs - T/P/R/BP	Routine, Per unit protocol, PACU & Post-op
Activity	
Strict bed rest	Routine, Until discontinued, Starting S, PACU & Post-op
[] Up with assistance	Routine, Until discontinued, Starting S
'	Specify: Up with assistance
	PACU & Post-op
[] Up ad lib	Routine, Until discontinued, Starting S
	Specify: Up ad lib PACU & Post-op
All meals out of bed	Routine, Until discontinued, Starting S
	All meals out of bed, PACU & Post-op
[] Elevate Head of bed 30 degrees	Routine, Until discontinued, Starting S Head of bed: 30 degrees
[] Head of bed flat	PACU & Post-op Routine, Until discontinued, Starting S Head of bed: flat PACU & Post-op
Nursing	
[] Telemetry	"And" Linked Panel

[1] Tolomotry monitoring	Pautina Continuous
[] Telemetry monitoring	Routine, Continuous Order: Place in Centralized Telemetry Monitor: EKG Monitoring Only
	(Telemetry Box)
	Reason for telemetry:
	Can be off of Telemetry for tests and baths? Yes
	PACU & Post-op
[] Telemetry Additional Setup Information	Routine, Continuous
[] Tolometry Additional Octop Information	High Heart Rate (BPM): 120
	Low Heart Rate(BPM): 50
	High PVC's (per minute): 10
	High SBP(mmHg): 175
	Low SBP(mmHg): 100
	High DBP(mmHg): 95
	Low DBP(mmHg): 40
	Low Mean BP: 60
	High Mean BP: 120
	Low SPO2(%): 94
	PACU & Post-op
] Assess operative site	Routine, Every 8 hours, PACU & Post-op
] Assess for Nausea	Routine, Until discontinued, Starting S
-	Assess: for Nausea
	PACU & Post-op
1 Assess cath site	Routine, Until discontinued, Starting S, PACU & Post-op
Assess Lumbar drain dressing and notify if satu	
	Assess: Lumbar drain dressing and notify if saturated.
	PACU & Post-op
Assess for pain	Routine, Until discontinued, Starting S
1 / tesess for pain	Assess: for pain
	PACU & Post-op
] Neurological assessment	Routine, Until discontinued, Starting S
1 Wodrological acceptant	Assessment to Perform:
	PACU & Post-op
] Peripheral vascular assessment	Routine, Until discontinued, Starting S, PACU & Post-op
1 Intake and output	Routine, Every shift, PACU & Post-op
X] Height and weight	Routine, Once For 1 Occurrences
7.1	On admission, PACU & Post-op
] Surgical/incision site care	Routine, Once
1 - 59	Location:
	Site:
	Apply:
	Dressing Type:
	Open to air?
	PACU & Post-op
] Reinforce dressing	Routine, As needed
-	Reinforce with:
	If saturated., PACU & Post-op
Drain care	Routine, Until discontinued, Starting S
-	Drain 1:
	Drain 2:
	Drain 3:
	Drain 4:
	Drain 4: All Drains:
] Lumbar drain care	All Drains:
] Lumbar drain care	All Drains: PACU & Post-op
] Lumbar drain care	All Drains: PACU & Post-op Routine, Until discontinued, Starting S Lumbar drain mgmt:
	All Drains: PACU & Post-op Routine, Until discontinued, Starting S Lumbar drain mgmt: PACU & Post-op
] Place antiembolic stockings	All Drains: PACU & Post-op Routine, Until discontinued, Starting S Lumbar drain mgmt: PACU & Post-op Routine, Once, PACU & Post-op
Lumbar drain care Place antiembolic stockings Straight cath	All Drains: PACU & Post-op Routine, Until discontinued, Starting S Lumbar drain mgmt: PACU & Post-op Routine, Once, PACU & Post-op Routine, Once
Place antiembolic stockings	All Drains: PACU & Post-op Routine, Until discontinued, Starting S Lumbar drain mgmt: PACU & Post-op Routine, Once, PACU & Post-op

,	Routine, Once Type:
	Size:
	Urinometer needed: If unable to void after second attempt at straight cath, insert Foley and cal
	physician, PACU & Post-op
	Routine, Until discontinued, Starting S Orders: Maintain
	to gravity/bedside drain, PACU & Post-op
[X] Notify Physician if unable to void after second attempt at straight cath and Foley inserted	Routine, Until discontinued, Starting S, PACU & Post-op
[] Cervical collar - Soft	Routine, Once
	Type of Collar to Apply: Soft cervical collar Special Instructions: Obtain from central supply PACU & Post-op
[] Cervical collar - Philadelphia	Routine, Once
	Type of Collar to Apply: Philadelphia Collar Special Instructions: Obtain from central supply PACU & Post-op
[] Cervical collar - Miami J	Routine, Once
	Type of Collar to Apply: Miami J Collar Special Instructions: Obtain from orthotic provider. PACU & Post-op
[] TLSO Brace	Routine, Until discontinued, Starting S
	Left/Right:
	Gender Size:
	Sizes: Obtain from orthotic provider., PACU & Post-op
Patient position: lumbar sacral support	Routine, Until discontinued, Starting S
[]	Position:
	Additional instructions: lumbar sacral support
[] Call Raborn Orthotics at 713-349-8117 for applicat	Obtain from orthotic provider., PACU & Post-op ion of Routine, Until discontinued, Starting S, PACU & Post-op
[] Call Raborn Orthotics at 713-349-8117 for applicat orthotic device	Libit of Routine, Ontil discontinued, Starting 3, FACO & Post-op
[] No anticoagulants INcluding UNfractionated hepari	in Routine, Until discontinued, Starting S
	Reason for "No" order: PACU & Post-op
No anti-platelet agents INcluding aspirin	Routine, Until discontinued, Starting S
[]	Reason for "No" order:
	PACU & Post-op
Notify	
[X] Notify Physician if acute change in neurological sta	atus Routine, Until discontinued, Starting S, PACU & Post-op
[X] Notify Physician of No Bowel Movement for more t hours	han 72 Routine, Until discontinued, Starting S, PACU & Post-op
Diet	
[] Diet - Clear liquids (advance as tolerated to Regula	
	Diet(s): Clear Liquids Advance Diet as Tolerated? Yes
	Target Diet: Regular
	Advance target diet criteria: Please assess bowel sounds
	between progressions. Liquid Consistency:
	Fluid Restriction:
	Foods to Avoid:
	PACU & Post-op

[] Diet - Regular	Diet effective now, Starting S
[] Dict - Regular	Diet(s): Regular
	Advance Diet as Tolerated?
	Liquid Consistency:
	Fluid Restriction:
	Foods to Avoid:
	PACU & Post-op
[] Diet - 2000 Kcal/225 gm Carb	Diet effective now, Starting S
11	Diet(s): 2000 Kcal/225 gm Carbohydrate
	Advance Diet as Tolerated?
	Liquid Consistency:
	Fluid Restriction:
	Foods to Avoid:
	PACU & Post-op
[] Diet - Full liquids	Diet effective now, Starting S
	Diet(s): Full Liquids
	Advance Diet as Tolerated?
	Liquid Consistency:
	Fluid Restriction:
	Foods to Avoid:
	PACU & Post-op
[] Diet	Diet effective now, Starting S
	Diet(s):
	Other Options:
	Advance Diet as Tolerated?
	Liquid Consistency:
	Fluid Restriction:
	Foods to Avoid:
	PACU & Post-op
Education	
Patient education - Activity	Routine, Once
[] Talletit education - Activity	Patient/Family:
	Education for: Activity
	PACU & Post-op
[X] Patient education - Deep breathing and coughing	Routine, Once
exercises	Patient/Family:
	Education for: Other (specify)
	Specify: Deep breathing and coughing exercises
	PACU & Post-op
[X] Patient education - Incentive spirometry	Routine, Once
	Patient/Family:
	Education for: Incentive spirometry
	PACU & Post-op
[X] Patient education - Pain management	Routine, Once
	Patient/Family:
	Education for: Other (specify)
	On a sife of Dalar and a superior to
	Specify: Pain management
	PACU & Post-op
[] Patient education - Smoking cessation	PACU & Post-op Routine, Once
[] Patient education - Smoking cessation	PACU & Post-op Routine, Once Patient/Family:
[] Patient education - Smoking cessation	PACU & Post-op Routine, Once Patient/Family: Education for: Smoking cessation counseling
	PACU & Post-op Routine, Once Patient/Family: Education for: Smoking cessation counseling PACU & Post-op
[] Patient education - Smoking cessation [X] Patient education - Wound care	PACU & Post-op Routine, Once Patient/Family: Education for: Smoking cessation counseling PACU & Post-op Routine, Once
	PACU & Post-op Routine, Once Patient/Family: Education for: Smoking cessation counseling PACU & Post-op Routine, Once Patient/Family:
	PACU & Post-op Routine, Once Patient/Family: Education for: Smoking cessation counseling PACU & Post-op Routine, Once Patient/Family: Education for: Other (specify)
	PACU & Post-op Routine, Once Patient/Family: Education for: Smoking cessation counseling PACU & Post-op Routine, Once Patient/Family: Education for: Other (specify) Specify: Wound care
	PACU & Post-op Routine, Once Patient/Family: Education for: Smoking cessation counseling PACU & Post-op Routine, Once Patient/Family: Education for: Other (specify)

IV Fluids

IV Fluids (Single Response)

() lactated Ringer's infusion

() sodium chloride 0.9 % infusion	intravenous, continuous, Post-op
() sodium chloride 0.9 % with potassium chloride 20 infusion	
() dextrose 5 % and sodium chloride 0.45 % with potassium chloride 20 mEq/L infusion - for NPO F	intravenous, continuous, Post-op Patients
Medications	
Steroids (Single Response)	
() dexamethasone (DECADRON) IV	4 mg, intravenous, every 6 hours scheduled, Post-op
() methylPREDNISolone sodium succinate (Solu-MEDROL) injection	40 mg, intravenous, every 6 hours scheduled, Post-op
() methylPREDNISolone (MEDROL PAK) dose pac	k (start
in AM)	
THIS A PANEL. DO NOT EDIT.	
[] methylPREDNISolone (MEDROL) tablet	8 mg, oral, before breakfast - one time, For 1 Doses, Post-op
[] methylPREDNISolone (MEDROL) tablet	4 mg, oral, after lunch - one time, S at 12:00 PM, For 1 Doses, Post-op
[] methylPREDNISolone (MEDROL) tablet	4 mg, oral, after dinner - one time, For 1 Doses, Post-op
	All day-1 doses may be given (up to 6 tablets) may be given at one time based on time of day.
[] methylPREDNISolone (MEDROL) tablet	8 mg, oral, nightly - one time, For 1 Doses, Post-op
	All day-1 doses may be given (up to 6 tablets) may be given at one time
	based on time of day.
[] methylPREDNISolone (MEDROL) tablet	4 mg, oral, 3 times daily around food, Starting S+1, For 3 Doses, Post-op
[] methylPREDNISolone (MEDROL) tablet	8 mg, oral, nightly - one time, Starting S+1, For 1 Doses, Post-op
[] methylPREDNISolone (MEDROL) tablet	4 mg, oral, 4 times daily tapering, Starting S+2, Post-op
Medications	
[] pantoprazole (PROTONIX) IV or ORAL	"Or" Linked Panel
[] pantoprazole (PROTONIX) EC tablet	40 mg, oral, daily at 0600, Post-op Indication(s) for Proton Pump Inhibitor (PPI) Therapy:
[] pantoprazole (PROTONIX) 40 mg in sodium chloride 0.9 % 10 mL injection	40 mg, intravenous, daily at 0600, Post-op Indication(s) for Proton Pump Inhibitor (PPI) Therapy:
Medications - Bowel Management	(-),
	AZ manual O Constant Library
[] polyethylene glycol (MIRALAX) packet	17 g, oral, 2 times daily, Post-op
[] Stool Softener Options (Single Response)	400 10 farm 1 latter Dock
() docusate sodium (COLACE) capsule	100 mg, oral, 2 times daily, Post-op
() sennosides-docusate sodium (SENOKOT-S) 8.6-50 mg per tablet	2 tablet, oral, nightly, Post-op
Antibiotics - NOT HMWB (Single Response)	
() Antibiotics - Neurosurgery - patients with surgical drains	site
[] cefazolin (ANCEF) IV - until drains removed	1 g, intravenous, every 8 hours, Post-op
	Administer until all drains removed.
	Type of Therapy: New Anti-Infective Order
	Reason for Therapy: Surgical Prophylaxis
[] cefepime (MAXIPIME) IV - until drains	1 g, intravenous, every 12 hours, Post-op
removed	Administer until all drains removed.
	Type of Therapy: New Anti-Infective Order
[] vancemyoin (\/ANCOCINI\)4!! 4!!:	Reason for Therapy: Surgical Prophylaxis
[] vancomycin (VANCOCIN) - until drains	1 g, intravenous, every 12 hours, Post-op Administer until all drains removed.
removed	Type of Therapy: New Anti-Infective Order
	Reason for Therapy: New Anti-Infective Order Reason for Therapy: Surgical Prophylaxis
	Indication:
() Antibiotics - Neurosurgery - patients withOUT sur	
.,	=

site drains

[] cefazolin (ANCEF) IV	1 g, intravenous, once, Starting H, For 1 Doses, Post-op Type of Therapy: New Anti-Infective Order Reason for Therapy: Surgical Prophylaxis
[] cefepime (MAXIPIME) IV	1 g, intravenous, once, Starting H, For 1 Doses, Post-op Type of Therapy: New Anti-Infective Order Reason for Therapy: Surgical Prophylaxis
[] vancomycin (VANCOCIN)	1 g, intravenous, once, Starting H, For 1 Doses, Post-op Type of Therapy: New Anti-Infective Order Reason for Therapy: Surgical Prophylaxis Indication:
Antibiotics - HMWB Only (Single Response)	
Antibiotics - Neurosurgery - patients with surgica drains	
[] cefazolin (ANCEF) IV - until drains removed	1 g, intravenous, every 8 hours Reason for Therapy: Surgical Prophylaxis
[] cefepime (MAXIPIME) IV	1 g, intravenous, every 12 hours Reason for Therapy: Surgical Prophylaxis
[] vancomycin (VANCOCIN) IV	1,000 mg, intravenous, every 12 hours Reason for Therapy: Surgical Prophylaxis
Antibiotics - Neurosurgery - patients withOUT sur site drains	
[] cefazolin (ANCEF) IV	1 g, intravenous, every 8 hours Reason for Therapy: Surgical Prophylaxis
[] cefepime (MAXIPIME) IV	1 g, intravenous, every 12 hours Reason for Therapy: Surgical Prophylaxis
[] vancomycin (VANCOCIN) IV	1,000 mg, intravenous, every 12 hours Reason for Therapy: Surgical Prophylaxis
Antiemetics	
[X] ondansetron (ZOFRAN) IV or Oral (Selection Re	quired) "Or" Linked Panel
[X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet	4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is able to tolerate oral medication.
[X] ondansetron (ZOFRAN) 4 mg/2 mL injection	4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.
promethazine (PHENERGAN) IV or Oral or Recta	
[] promethazine (PHENERGAN) 12.5 mg IV	12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required.
[] promethazine (PHENERGAN) tablet	12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication.
[] promethazine (PHENERGAN) suppository	12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication.
[] scopolamine (TRANSDERM-SCOP) 1.5 mg (1 m days) - For Patients LESS than 65 years old	ng over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op
PRN Medications - Symptom Management	
[] acetaminophen (TYLENOL) tablet	650 mg, oral, every 6 hours PRN, fever, Temperature greater than 101 F, Post-op
[] Itching - Neurosurgery medications (Single Resp Avoid diphenhydramine use in patients over 70 y	
() cetirizine (ZyrTEC) tablet	5 mg, oral, daily PRN, itching, Post-op
() diphenhydrAMINE (BENADRYL) injection	12.5 mg, intravenous, every 12 hours PRN, itching, Post-op
PRN Medications - Bowel Management (Single Re	esponse)
() magnesium hydroxide suspension	30 mL, oral, daily PRN, constipation, Post-op

() bisacodyl (DULCOLAX) EC tablet	5 mg, oral, daily PRN, constipation, Post-op
() bisacodyl (DULCOLAX) suppository	10 mg, rectal, daily PRN, constipation, Post-op
() magnesium citrate solution	150 mL, oral, daily PRN, constipation, For 2 Doses, Post-op
PRN Medications - Bowel Management	
[] saline,mineral oil,glycerin (S.M.O.G.) enema	a 180 mL, rectal, once, Post-op
Muscle Relaxants (Single Response)	
() methocarbamol (ROBAXIN) 500 mg in sodi	
0.9 % 100 mL IVPB () methocarbamol (ROBAXIN) tablet	muscle spasms, Post-op
() cyclobenzaprine (FLEXERIL) tablet	500 mg, oral, every 8 hours PRN, muscle spasms, Post-op 5 mg, oral, every 8 hours PRN, muscle spasms, Post-op
Muscle Relaxants - Refractory Treatments (S	
() diazepam (VALIUM) injection	2.5 mg, intravenous, every 8 hours PRN, muscle spasms, inadequate muscle spasm relief following administration of
	other agents, Post-op
	Indication(s): Other
	Specify: Muscle Relaxant
() diazepam (VALIUM) tablet	2.5 mg, oral, every 8 hours PRN, muscle spasms, inadequate muscle spasm relief following administration of other agents, Post-op
	Indication(s): Other
	Specify: Muscle Relaxant
PRN Medications - Pain - Pain Score (1-3) (S	ingle Response)
() traMADol (ULTRAM) tablet	25 mg, oral, every 4 hours PRN, mild pain (score 1-3), Post-op Maximum Daily Dose: 200 mg/day
	,,,,,,,,,,,
PCA Medications (Single Response)	
() morPHINE PCA 30 mg/30 mL	
[] morPHINE 30 mg/30 mL PCA	Loading Dose (optional): Not Ordered PCA Dose: 1 mg Lockou
11	Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four
	hour dose limit): 20 mg
	intravenous, continuous, Post-op
	Management of breakthrough pain. Administer only if respiratory rate 12
	per minute or more and POSS level of 2 or less. If more than 2 bolus
	doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years
	old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg
	every {Bolus Frequency:26659::"3"} hours as needed. If pain persists,
	may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE.
	Adjust doses for age, renal function or other factors.
[] Vital signs - T/P/R/BP	Routine, Per unit protocol
	 Initially and every 30 minutes for 1 hour after PCA started, bolus
	administration or dose change; then
	- Every hour x 2 starting second hour after PCA started, bolus
	administered or dose change; then
	 Every 4 hours until PCA therapy is discontinued. Immediately following PCA administration tubing change, Post-op
[] Richmond agitation sedation scale	Routine, Once
	Hold infusion daily at:
	Target RASS:
	BIS Monitoring (Target BIS: 40-60):
	60 minutes after administration of pain medication AND every 4 hours.
	Assess and document side effects of at least every 4 hours for duration of
I	therapy and when patient complains of pain and/or side effects., Post-op

[]	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason
		- Inadequate analgesia
		- Prior to administration of any other narcotics, antiemetics, or sedatives
		other than those ordered by the prescriber responsible for IV PCA therapy
		- PCA pump discontinued by any service other than the prescriber
		responsible for IV PCA therapy, Post-op
[]	Stop the PCA pump and call ordering	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or
.,	physician and/or CERT team for any of the	less
	following:	- Severe and/or recent confusion or disorientation
	ionownig.	- POSS sedation level 4: Somnolent and difficult to arouse
		- Sustained hypotension (SBP less than 90)
		- Excessive nausea or vomiting
		- Urinary retention, Post-op
[]	naloxone (NARCAN) 0.4 mg/mL injection	0.2 mg, intravenous, once PRN, respiratory depression, as needed for
	0.2 mg	respiratory rate 8 per minute or less OR patient somnolent and difficult to
	-	arouse (POSS GREATER than 3)., Post-op
		Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4
		mg). If naloxone is needed, please call the ordering physician and/or
		CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15
		minutes for 3 times.
\ b .	udramarDLIONE DOA (DILALIDID) 45 mar/20 ml	
	ydromorPHONE PCA (DILAUDID) 15 mg/30 mL	
[]	hydromorPHONE (DILAUDID) 15 mg/30 mL	Loading Dose (optional): Not Ordered PCA Dose: 0.2
	PCA	mg Lockout: Not Ordered Continuous Dose: 0 mg/hr MAX
		(Four hour dose limit): 3 mg
		intravenous, continuous, Post-op
		Management of breakthrough pain. Administer only if respiratory rate 12
		per minute or more and POSS level of 2 or less. If more than 2 bolus
		doses in 12 hours or if pain persists after increase in demand dose, call
		ordering prescriber. For breakthrough pain in patients ages 19-59 years
		old with normal renal function, may bolus {Bolus Dose:26662::"0.2"} mg
		every {Bolus Frequency:26663::"3"} hours as needed. If pain persists,
		may increase PCA demand dose by {PCA Dose:26664::"0.1"} mg ONCE.
		Adjust doses for age, renal function or other factors.
		Turn Off PCA Continuous Dose (Basal Rate) On Date:
		Turn Off PCA Continuous Dose (Basal Rate) At Time:
[]	Vital signs - T/P/R/BP	Routine, Per unit protocol
		- Initially and every 30 minutes for 1 hour after PCA started, bolus
		administration or dose change; then
		- Every hour x 2 starting second hour after PCA started, bolus
		administered or dose change; then
		- Every 4 hours until PCA therapy is discontinued.
		- Immediately following PCA administration tubing change, Post-op
IJ	Richmond agitation sedation scale	Routine, Once
		Hold infusion daily at:
		Target RASS:
		BIS Monitoring (Target BIS: 40-60):
		60 minutes after administration of pain medication AND every 4 hours.
		Assess and document side effects of at least every 4 hours for duration of
		therapy and when patient complains of pain and/or side effects., Post-op
<u> </u>	Notify Physician (Specify)	· · · · · · · · · · · · · · · · · · ·
[]	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued
		for any reason
		- Inadequate analgesia
		- Prior to administration of any other narcotics, antiemetics, or sedatives
		other than those ordered by the prescriber responsible for IV PCA therapy
		- PCA pump discontinued by any service other than the prescriber
		responsible for IV PCA therapy, Post-op
		127

[]	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op
[]	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
() fe	entaNYL PCA (SUBLIMAZE) 1500 mcg/30 mL	Timidade for a timod.
(,[]		Loading Dose (optional): Not Ordered PCA Dose: 10 mcg Lockout (recommended 6-8 min): Not Ordered Continuous Dose: 0 mcg/hr MAX (Four hour dose limit): 150 mcg intravenous, continuous, Post-op **Due to fentaNYL 600 mcg/30 mL shortages, the new standard for all facilities will be fentaNYL 1500 mcg/30 mL. This concentration is 2.5 x more concentrated.**
		Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patient 19-59 years old, may bolus {Bolus Dose:26656::"25"} mcg every {Bolus Frequency:26655::"2"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26654::"10"} mcg ONCE. Adjust doses for age, renal function or other factors. Turn Off PCA Continuous Dose (Basal Rate) On Date: Turn Off PCA Continuous Dose (Basal Rate) At Time:
[]	Vital signs - T/P/R/BP	Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued Immediately following PCA administration tubing change, Post-op
[]	Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op
[]	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
[]	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op

[]	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
CA	Medications (Single Response)	
_m	norPHINE PCA 30 mg/30 mL	
[]	morPHINE 30 mg/30 mL PCA	Loading Dose (optional): Not Ordered PCA Dose: 1 mg Locko Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op
		Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE Adjust doses for age, renal function or other factors.
[]	Vital signs - T/P/R/BP	Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued Immediately following PCA administration tubing change, Post-op
[]	Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration therapy and when patient complains of pain and/or side effects., Post-op
[]	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinue for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA thera - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
[]	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op
[]	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult t arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.

	hydromorPHONE (DILAUDID) 15 mg/30 mL PCA	Loading Dose (optional): Not Ordered PCA Dose: 0.2 mg Lockout: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 3 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26662::"0.2"} mg every {Bolus Frequency:26663::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26664::"0.1"} mg ONCE Adjust doses for age, renal function or other factors. Turn Off PCA Continuous Dose (Basal Rate) On Date: Turn Off PCA Continuous Dose (Basal Rate) At Time:
[]	Vital signs - T/P/R/BP	Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued. - Immediately following PCA administration tubing change, Post-op
[]	Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration therapy and when patient complains of pain and/or side effects., Post-op
[]	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinue for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA thera - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
[]	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op
[]	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.

	fentaNYL (SUBLIMAZE) 600 mcg/30 mL PCA	Interval: I hour dose intraveno Managen per minut doses in ordering bolus {Bohours as {PCA Door other f	ading Dose: Not Ordered PCA Dose: 10 mcg Lockout Not Ordered Continuous Dose: 0 mcg/hr MAX (Four elimit): 150 mcg ous, continuous, Post-op onent of breakthrough pain. Administer only if respiratory rate 12 te or more and POSS level of 2 or less. If more than 2 bolus 12 hours or if pain persists after increase in demand dose, call prescriber. For breakthrough pain in patient 19-59 years old, may blus Dose:26656::"25"} mcg every {Bolus Frequency:26655::"2"} needed. If pain persists, may increase PCA demand dose by se:26654::"10"} mcg ONCE. Adjust doses for age, renal function factors.
			PCA Continuous Dose (Basal Rate) On Date. PCA Continuous Dose (Basal Rate) At Time:
[]	Vital signs - T/P/R/BP	Routine, - Initially administr - Every h administe - Every 4	Per unit protocol and every 30 minutes for 1 hour after PCA started, bolus ation or dose change; then our x 2 starting second hour after PCA started, bolus ered or dose change; then hours until PCA therapy is discontinued. ately following PCA administration tubing change, Post-op
	Richmond agitation sedation scale	Target RA BIS Moni 60 minute Assess a	sion daily at:
[]	Notify Physician (Specify)	Routine, for any re - Inadequ - Prior to other tha - PCA pu	Until discontinued, Starting S, - PCA pump infusion discontinued
[]	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, less - Severe - POSS s - Sustain - Excessi	Until discontinued, Starting S, - Respiratory rate 10 per minute or and/or recent confusion or disorientation sedation level 4: Somnolent and difficult to arouse ed hypotension (SBP less than 90) ve nausea or vomiting retention, Post-op
[]	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, in respirator arouse (FRepeat Nmg). If na	htravenous, once PRN, respiratory depression, as needed for ry rate 8 per minute or less OR patient somnolent and difficult to POSS GREATER than 3)., Post-op laloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 aloxone is needed, please call the ordering physician and/or am. Monitor vital signs (pulse oximetry, P/R/BP) every 15 for 3 times.
PRN	Medications - Pain - Pain Score (4-6) (Single I	Response)
. ,	cetaminophen-codeine (TYLENOL #3) 300-30 m ablet	g per	1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Do not exceed 3000 mg of acetaminophen daily from all sources.
() tr	aMADol (ULTRAM) tablet		50 mg, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Maximum Daily Dose: 200 mg/day

PRN Medications - Pain - Pain Score (7-10) (Single Response)

() acetaminophen-codeine (TYLENOL #3) 300-30 mg per tablet	 2 tablet, oral, every 6 hours PRN, severe pain (score 7-10), Post-op Do not exceed 3000 mg of acetaminophen daily from all sources.
Breakthrough Pain (Single Response)	
fentaNYL (SUBLIMAZE) injection	25 mcg, intravenous, every 2 hour PRN, other, pain (score: 4-10) - inadequate pain relief following administration of oral agents, Post-op Administer after pain re-assessment for inadequate pain relief
norphine 2 mg/mL injection	2 mg, intravenous, every 3 hours PRN, other, pain (score: 4-10) - inadequate pain relief following administration of oral agents, Post-op Administer after pain re-assessment for inadequate pain relief
() HYDROmorphone (DILAUDID) injection	0.5 mg, intravenous, every 3 hours PRN, other, pain (score: 4-10) - inadequate pain relief following administration of oral agents, Post-op Administer after pain re-assessment for inadequate pain relief
√TE	
DVT Risk and Prophylaxis Tool (Single Response) (Sel	ection Required) URL: "\appt1.pdf"
() Patient currently has an active order for therapeutic anticoagulant or VTE prophylaxis	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op
() LOW Risk of DVT (Selection Required) Low Risk Definition	17100 01 051 05
Low Risk Definition Age less than 60 years and NO other VTE risk factors [] Low Risk (Single Response) (Selection Required)	
Low Risk Definition Age less than 60 years and NO other VTE risk factors [] Low Risk (Single Response) (Selection Required) () Low risk of VTE Ro Lo ea	outine, Once
Low Risk Definition Age less than 60 years and NO other VTE risk factors [] Low Risk (Single Response) (Selection Required) () Low risk of VTE Ro Lo ea PA) MODERATE Risk of DVT - Surgical (Selection Required)	outine, Once w risk: Due to low risk, no VTE prophylaxis is needed. Will encourga rly ambulation ACU & Post-op
Low Risk Definition Age less than 60 years and NO other VTE risk factors Low Risk (Single Response) (Selection Required) Low risk of VTE Rough Low Risk (Single Response) Rough Low Risk (Single Response) Rough Roug	outine, Once w risk: Due to low risk, no VTE prophylaxis is needed. Will encourga rly ambulation ACU & Post-op ed)
Low Risk Definition Age less than 60 years and NO other VTE risk factors [] Low Risk (Single Response) (Selection Required) () Low risk of VTE Ro Lo ea PA] MODERATE Risk of DVT - Surgical (Selection Required) Moderate Risk Definition Pharmacologic prophylaxis must be addressed. Mechal contraindicated. One or more of the following medical conditions: CHF, MI, lung disease, pneumonia, active inflammation stroke, rheumatologic disease, sickle cell disease, leg sickle 60 and above Central line	outine, Once w risk: Due to low risk, no VTE prophylaxis is needed. Will encourga rly ambulation ACU & Post-op ed)
Low Risk Definition Age less than 60 years and NO other VTE risk factors [] Low Risk (Single Response) (Selection Required) () Low risk of VTE Ro Lo ea PA [] MODERATE Risk of DVT - Surgical (Selection Required) Moderate Risk Definition Pharmacologic prophylaxis must be addressed. Mechal contraindicated. One or more of the following medical conditions: CHF, MI, lung disease, pneumonia, active inflammation stroke, rheumatologic disease, sickle cell disease, leg sage 60 and above Central line History of DVT or family history of VTE Anticipated length of stay GREATER than 48 hours Less than fully and independently ambulatory Estrogen therapy	outine, Once ow risk: Due to low risk, no VTE prophylaxis is needed. Will encourgately ambulation ACU & Post-op ed) anical prophylaxis is optional unless pharmacologic is n, dehydration, varicose veins, cancer, sepsis, obesity, previous
Low Risk Definition Age less than 60 years and NO other VTE risk factors [] Low Risk (Single Response) (Selection Required) () Low risk of VTE Ro Lo ea PA [] MODERATE Risk of DVT - Surgical (Selection Required) Moderate Risk Definition Pharmacologic prophylaxis must be addressed. Mecha contraindicated. One or more of the following medical conditions: CHF, MI, lung disease, pneumonia, active inflammation stroke, rheumatologic disease, sickle cell disease, leg sage 60 and above Central line History of DVT or family history of VTE Anticipated length of stay GREATER than 48 hours Less than fully and independently ambulatory	outine, Once ow risk: Due to low risk, no VTE prophylaxis is needed. Will encourgately ambulation ACU & Post-op ed) anical prophylaxis is optional unless pharmacologic is n, dehydration, varicose veins, cancer, sepsis, obesity, previous
Low Risk Definition Age less than 60 years and NO other VTE risk factors [] Low Risk (Single Response) (Selection Required) () Low risk of VTE Ro Lo ea PA [] MODERATE Risk of DVT - Surgical (Selection Required) Moderate Risk Definition Pharmacologic prophylaxis must be addressed. Mechal contraindicated. One or more of the following medical conditions: CHF, MI, lung disease, pneumonia, active inflammation stroke, rheumatologic disease, sickle cell disease, leg and Age 60 and above Central line History of DVT or family history of VTE Anticipated length of stay GREATER than 48 hours Less than fully and independently ambulatory Estrogen therapy Moderate or major surgery (not for cancer) Major surgery within 3 months of admission [] Moderate Risk (Selection Required)	outine, Once w risk: Due to low risk, no VTE prophylaxis is needed. Will encourga rly ambulation ACU & Post-op ed) anical prophylaxis is optional unless pharmacologic is n, dehydration, varicose veins, cancer, sepsis, obesity, previous swelling, ulcers, venous stasis and nephrotic syndrome
Low Risk Definition Age less than 60 years and NO other VTE risk factors [] Low Risk (Single Response) (Selection Required) () Low risk of VTE Ro Lo ea PA [] MODERATE Risk of DVT - Surgical (Selection Required) Moderate Risk Definition Pharmacologic prophylaxis must be addressed. Mechal contraindicated. One or more of the following medical conditions: CHF, MI, lung disease, pneumonia, active inflammation stroke, rheumatologic disease, sickle cell disease, leg and Age 60 and above Central line History of DVT or family history of VTE Anticipated length of stay GREATER than 48 hours Less than fully and independently ambulatory Estrogen therapy Moderate or major surgery (not for cancer) Major surgery within 3 months of admission [] Moderate Risk (Selection Required)	outine, Once w risk: Due to low risk, no VTE prophylaxis is needed. Will encourge rly ambulation ACU & Post-op ed) anical prophylaxis is optional unless pharmacologic is n, dehydration, varicose veins, cancer, sepsis, obesity, previous swelling, ulcers, venous stasis and nephrotic syndrome
Low Risk Definition Age less than 60 years and NO other VTE risk factors [] Low Risk (Single Response) (Selection Required) () Low risk of VTE Ro Lo ea PA [] MODERATE Risk of DVT - Surgical (Selection Required) Moderate Risk Definition Pharmacologic prophylaxis must be addressed. Mechal contraindicated. One or more of the following medical conditions: CHF, MI, lung disease, pneumonia, active inflammation stroke, rheumatologic disease, sickle cell disease, leg and Age 60 and above Central line History of DVT or family history of VTE Anticipated length of stay GREATER than 48 hours Less than fully and independently ambulatory Estrogen therapy Moderate or major surgery (not for cancer) Major surgery within 3 months of admission [] Moderate Risk (Selection Required) [] Moderate risk of VTE Ro Ro Ro Ro Ro Ro Ro Ro Ro R	outine, Once w risk: Due to low risk, no VTE prophylaxis is needed. Will encourgatly ambulation ACU & Post-op ed) enical prophylaxis is optional unless pharmacologic is n, dehydration, varicose veins, cancer, sepsis, obesity, previous swelling, ulcers, venous stasis and nephrotic syndrome outine, Once, PACU & Post-op cal

[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
() Contraindications exist for pharmacologic prop AND mechanical prophylaxis	hylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Resp (Selection Required)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:

() MODERATE Risk of DVT - Non-Surgical (Selection Required)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

[] Moderate Risk (Selection Required)	
[] Moderate risk of VTE	Routine, Once, PACU & Post-op
[] Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) (Selecti Required)	on
() Contraindications exist for pharmacologic propl Order Sequential compression device	hylaxis - "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
 Contraindications exist for pharmacologic proplements AND mechanical prophylaxis 	hylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Resp (Selection Required)	onse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, PACU & Post-op
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
() HIGH Risk of DVT - Surgical (Selection Required)	

() HIGH Risk of DVT - Surgical (Selection Required)

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

[] High Risk (Selection Required)	
[] High risk of VTE	Routine, Once, PACU & Post-op
[] High Risk Pharmacological Prophylaxis - Surgio (Single Response) (Selection Required)	cal Patient
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Res (Selection Required)	ponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response) (Se Required)	lection
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op

() HIGH Risk of DVT - Non-Surgical (Selection Required)

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

High Risk (Selection Required)High risk of VTE	Routine, Once, PACU & Post-op
1 High Risk Pharmacological Prophylaxis - Non-S	
Patient (Single Response) (Selection Required)	
() Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following
	contraindication(s):
	PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Res (Selection Required)	ponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S
· , ·	For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND	30 mg, subcutaneous, 2 times daily, Starting S
CrCl GREATER than 30 mL/min	For Patients weight between 100-139 kg and CrCl GREATER than 30
	mL/min
() patients weight 140 kg or GREATER AND	40 mg, subcutaneous, 2 times daily, Starting S
CrCl GREATER than 30 mL/min	For Patients weight 140 kg or GREATER and CrCl GREATER than 3
	mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily
	If the patient does not have a history of or suspected case of
	Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication
	Contraindicated in patients LESS than 50kg, prior to surgery/invasive
	procedure, or CrCl LESS than 30 mL/min.
	This patient has a history of or suspected case of Heparin-Induced
(A) It is a size of a section (A) to the size	Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended	5,000 Units, subcutaneous, every 12 hours
for patients with high risk of bleeding, e.g.	Recommended for patients with high risk of bleeding, e.g. weight LESS
weight < 50kg and age > 75yrs)	than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700
() Dhamaay amaylt ta managa wanfarin	Indication:
() Pharmacy consult to manage warfarin	STAT, Until discontinued, Starting S
(COUMADIN)	Indication:
Mechanical Prophylaxis (Single Response) (Se Required)	
() Contraindications exist for mechanical	Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following contraindication(s PACU & Post-op
() Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op

Required)

HIGH Risk of DVT - Surgical (Hip/Knee) (Selection

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

[] High Risk (Selection Required) [] High risk of VTE [] High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response) (Selection Required) () Contraindications exist for pharmacologic prophylaxis () apixaban (ELIQUIS) tablet () aspirin chewable tablet () aspirin (ECOTRIN) enteric coated tablet () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe () enoxaparin	
High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response) (Selection Required) Contraindications exist for pharmacologic prophylaxis	
(Arthroplasty) Surgical Patient (Single Response) (Selection Required) () Contraindications exist for pharmacologic prophylaxis	
() Contraindications exist for pharmacologic prophylaxis () apixaban (ELIQUIS) tablet () aspirin chewable tablet () aspirin (ECOTRIN) enteric coated tablet () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For	
prophylaxis No pharmacologic VTE prophylaxis due to the following contraindication(s): () apixaban (ELIQUIS) tablet 2.5 mg, oral, every 12 hours, Starting S+1 Indications: () aspirin chewable tablet () aspirin (ECOTRIN) enteric coated tablet () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min. () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL)	
contraindication(s): () apixaban (ELIQUIS) tablet 2.5 mg, oral, every 12 hours, Starting S+1 Indications: () aspirin chewable tablet () aspirin (ECOTRIN) enteric coated tablet () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min. () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI	
() apixaban (ELIQUIS) tablet 2.5 mg, oral, every 12 hours, Starting S+1 Indications: () aspirin chewable tablet () aspirin (ECOTRIN) enteric coated tablet () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min. () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) For Patients with CrCL LESS than 30 mL/min.	
Indications: () aspirin chewable tablet	
() aspirin (ECOTRIN) enteric coated tablet 162 mg, oral, daily, Starting S+1 () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI	
() enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI STARTING S+1) () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI STARTING S+1)	
() enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI	
() enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1)	
Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min. () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI	
Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI	CAL),
() enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI	
Patients weight between 100-139 kg and Starting S+1	CAL),
CrCl GREATER than 30 mL/min For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.	
() enoxaparin (LOVENOX) syringe - For 40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI	CAL),
Patients weight between 140 kg or Starting S+1	
GREATER and CrCl GREATER than 30 For Patients weight 140 kg or GREATER and CrCl GREATER to	han 30
mL/min mL/min	
() fondaparinux (ARIXTRA) injection 2.5 mg, subcutaneous, daily, Starting S+1	
If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this me	dication
Contraindicated in patients LESS than 50kg, prior to surgery/inva	
procedure, or CrCl LESS than 30 mL/min	SIVC
This patient has a history of or suspected case of Heparin-Induce	ed
Thrombocytopenia (HIT):	
() heparin (porcine) injection 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM	
() heparin (porcine) injection (Recommended 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM	
for patients with high risk of bleeding, e.g. Recommended for patients with high risk of bleeding, e.g. weight	LESS
weight < 50kg and age > 75yrs) than 50kg and age GREATER than 75yrs.	
() rivaroxaban (XARELTO) tablet for hip or 10 mg, oral, daily at 0600 (TIME CRITICAL), Starting S+1	
knee arthroplasty planned during this To be Given on Post Op Day 1.	
admission Indications:	
() warfarin (COUMADIN) tablet oral, daily at 1700, Starting S+1 Indication:	
() Pharmacy consult to manage warfarin STAT, Until discontinued, Starting S Indication:	

Required)

Mechanical Prophylaxis (Single Response) (Selection

	() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
	() Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
DV	Γ Risk and Prophylaxis Tool (Single Response)	URL: "\appt1.pdf"
()	Patient currently has an active order for therapeutic anticoagulant or VTE prophylaxis	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op
()	LOW Risk of DVT (Selection Required)	
	Low Risk Definition Age less than 60 years and NO other VTE risk factor	ors
l i] Low Risk (Single Response) (Selection Required)
'	() Low risk of VTE	Routine, Once
	() =	Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation PACU & Post-op
()	MODERATE Risk of DVT - Surgical (Selection Requ	uired)
i	contraindicated. One or more of the following medical conditions: CHF, MI, lung disease, pneumonia, active inflamma	chanical prophylaxis is optional unless pharmacologic is ation, dehydration, varicose veins, cancer, sepsis, obesity, previous eg swelling, ulcers, venous stasis and nephrotic syndrome
'	Moderate risk of VTE	Routine, Once, PACU & Post-op
Ī	 Moderate Risk Pharmacological Prophylaxis - Su Patient (Single Response) (Selection Required) 	
	() Contraindications exist for pharmacologic proph BUT order Sequential compression device	ylaxis "And" Linked Panel
	[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
	[] Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
	() Contraindications exist for pharmacologic proph AND mechanical prophylaxis	ylaxis "And" Linked Panel
	[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
	[] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACLL& Post-on

() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:

MODERATE Risk of DVT - Non-Surgical (Selection Required)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

Moderate risk of VTE	Routine, Once, PACU & Post-op
Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) (Select Required)	ion
) Contraindications exist for pharmacologic prop Order Sequential compression device	hylaxis - "And" Linked Panel
Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op

AND mechanical prophylaxis

[] Contraindications exist for pharmacolo prophylaxis	gic Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Sing (Selection Required)	e Response)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
() patients with CrCL LESS than 30 mL/r	nin 30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg A CrCl GREATER than 30 mL/min	ND 30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER A CrCl GREATER than 30 mL/min	ND 40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, PACU & Post-op
() heparin (porcine) injection (Recommend for patients with high risk of bleeding, e weight < 50kg and age > 75yrs)	g. Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
) HIGH Risk of DVT - Surgical (Selection Red	uired)

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

[] High Risk (Selection Required) [] High risk of VTE	Routine, Once, PACU & Post-op
[] High Risk Pharmacological Prophylaxis - Surg (Single Response) (Selection Required)	ical Patient
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Res	sponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min

() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response) (Se Required)	lection
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
HIGH Risk of DVT - Non-Surgical (Selection Requ	uired)

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

[] High Risk (Selection Required)		
[] High risk of VTE	gh risk of VTE Routine, Once, PACU & Post-op	
[] High Risk Pharmacological Prophylaxis - Non-St Patient (Single Response) (Selection Required)	urgical	
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op	
() enoxaparin (LOVENOX) injection (Single Resp (Selection Required)	onse)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S	
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min	
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	

() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
 () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) 	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response) (Sele Required)	ection
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
() HIGH Risk of DVT - Surgical (Hip/Knee) (Selection Required)	

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

[] High Risk (Selection Required)	
[] High risk of VTE	Routine, Once, PACU & Post-op
[] High Risk Pharmacological Prophylaxis - Hip of (Arthroplasty) Surgical Patient (Single Respondance) (Selection Required)	
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1 Indications:
() aspirin chewable tablet	162 mg, oral, daily, Starting S+1
() aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1
() enoxaparin (LOVENOX) injection (Single Re- (Selection Required)	sponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
() enoxaparin (LOVENOX) syringe	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min.

() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.
() enoxaparin (LOVENOX) syringe - For Patients weight between 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission	10 mg, oral, daily at 0600 (TIME CRITICAL), Starting S+1 To be Given on Post Op Day 1. Indications:
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response) (Sele Required)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
Labs	
Labs Laboratory	
Laboratory [] Type and screen	Once, PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential	Once, PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential [] Hemoglobin and hematocrit	Once, PACU & Post-op Once In Recovery room., PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential [] Hemoglobin and hematocrit [] Partial thromboplastin time	Once, PACU & Post-op Once In Recovery room., PACU & Post-op Once, PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential [] Hemoglobin and hematocrit [] Partial thromboplastin time [] Prothrombin time with INR	Once, PACU & Post-op Once In Recovery room., PACU & Post-op Once, PACU & Post-op Once, PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential [] Hemoglobin and hematocrit [] Partial thromboplastin time [] Prothrombin time with INR [] Basic metabolic panel	Once, PACU & Post-op Once In Recovery room., PACU & Post-op Once, PACU & Post-op Once, PACU & Post-op Once, PACU & Post-op Once, PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential [] Hemoglobin and hematocrit [] Partial thromboplastin time [] Prothrombin time with INR [] Basic metabolic panel [] Calcium level	Once, PACU & Post-op Once In Recovery room., PACU & Post-op Once, PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential [] Hemoglobin and hematocrit [] Partial thromboplastin time [] Prothrombin time with INR [] Basic metabolic panel [] Calcium level [] Magnesium level	Once, PACU & Post-op Once In Recovery room., PACU & Post-op Once, PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential [] Hemoglobin and hematocrit [] Partial thromboplastin time [] Prothrombin time with INR [] Basic metabolic panel [] Calcium level [] Magnesium level [] Phosphorus level	Once, PACU & Post-op Once In Recovery room., PACU & Post-op Once, PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential [] Hemoglobin and hematocrit [] Partial thromboplastin time [] Prothrombin time with INR [] Basic metabolic panel [] Calcium level [] Magnesium level [] Phosphorus level [] Blood gas, arterial	Once, PACU & Post-op Once In Recovery room., PACU & Post-op Once, PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential [] Hemoglobin and hematocrit [] Partial thromboplastin time [] Prothrombin time with INR [] Basic metabolic panel [] Calcium level [] Magnesium level [] Phosphorus level [] Blood gas, arterial	Once, PACU & Post-op Once In Recovery room., PACU & Post-op Once, PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential [] Hemoglobin and hematocrit [] Partial thromboplastin time [] Prothrombin time with INR [] Basic metabolic panel [] Calcium level [] Magnesium level [] Phosphorus level [] Phosphorus level [] Blood gas, arterial [] Urinalysis screen and microscopy, with reflex to cu	Once, PACU & Post-op Once In Recovery room., PACU & Post-op Once, PACU & Post-op Once Specimen Source: Urine Specimen Site: PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential [] Hemoglobin and hematocrit [] Partial thromboplastin time [] Prothrombin time with INR [] Basic metabolic panel [] Calcium level [] Magnesium level [] Phosphorus level [] Phosphorus level [] Blood gas, arterial [] Urinalysis screen and microscopy, with reflex to cu	Once, PACU & Post-op Once In Recovery room., PACU & Post-op Once, PACU & Post-op Once Specimen Source: Urine Specimen Site: PACU & Post-op AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential [] Hemoglobin and hematocrit [] Partial thromboplastin time [] Prothrombin time with INR [] Basic metabolic panel [] Calcium level [] Magnesium level [] Phosphorus level [] Phosphorus level [] Blood gas, arterial [] Urinalysis screen and microscopy, with reflex to cu	Once, PACU & Post-op Once In Recovery room., PACU & Post-op Once, PACU & Post-op Once Specimen Source: Urine Specimen Site: PACU & Post-op AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential [] Hemoglobin and hematocrit [] Partial thromboplastin time [] Prothrombin time with INR [] Basic metabolic panel [] Calcium level [] Magnesium level [] Phosphorus level [] Blood gas, arterial [] Urinalysis screen and microscopy, with reflex to cu	Once, PACU & Post-op Once In Recovery room., PACU & Post-op Once, PACU & Post-op Once Specimen Source: Urine Specimen Site: PACU & Post-op AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op
Laboratory [] Type and screen [] CBC with platelet and differential [] Hemoglobin and hematocrit [] Partial thromboplastin time [] Prothrombin time with INR [] Basic metabolic panel [] Calcium level [] Magnesium level [] Phosphorus level [] Phosphorus level [] Blood gas, arterial [] Urinalysis screen and microscopy, with reflex to cu	Once, PACU & Post-op Once In Recovery room., PACU & Post-op Once, PACU & Post-op Once Specimen Source: Urine Specimen Site: PACU & Post-op AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op

[] Hemoglobin

AM draw repeats For 3 Occurrences, PACU & Post-op

Imaging	
СТ	
[] CT Convical Spine We Contract	Pouting 1 time imaging For 1 PACIL® Post on
CT Cervical Spine Wo Contrast CT Thoracic Spine Wo Contrast	Routine, 1 time imaging For 1 , PACU & Post-op Routine, 1 time imaging For 1 , PACU & Post-op
[] CT Lumbar Spine Wo Contrast	Routine, 1 time imaging For 1 , PACU & Post-op
[] Of Edition Opine Wo Contrast	Routine, I time imaging For 1, 1 Aco & Fost-op
X-ray	
[] Chest 1 Vw	Routine, 1 time imaging For 1 , PACU & Post-op
[] Chest 1 Vw in AM	Routine, 1 time imaging, Starting S+1 For 1 , PACU & Post-op
[] Chest 2 Vw	Routine, 1 time imaging For 1 , PACU & Post-op
[] XR Spine Scoliosos 2-3 Views	Routine, 1 time imaging For 1
	Please add 32 millimeter image calibration necklace to the
	field of view., PACU & Post-op
[] Cervical Spine 1 Vw	Routine, 1 time imaging For 1 , PACU & Post-op
[] Cervical Spine 2 Or 3 Vw	Routine, 1 time imaging For 1 , PACU & Post-op
[] Thoracic Spine 1 Vw	Routine, 1 time imaging For 1 , PACU & Post-op
[] Lumbar Spine 1 Vw	Routine, 1 time imaging For 1 , PACU & Post-op
[] Lumbar Spine Ap Lateral Flexion And Extension	Routine, 1 time imaging For 1 , PACU & Post-op
[] Lumbar Spine Complete 4+ Vw	Routine, 1 time imaging For 1 , PACU & Post-op
[] Thoracolumbar Spine 2 Vw	Routine, 1 time imaging For 1 , PACU & Post-op
Respiratory	
Respiratory	
Oxygen therapy - Simple face mask	Routine, Continuous
[] Chygon thorapy Campio lade mack	Device: Simple Face Mask
	Rate in liters per minute: 6 lpm
	Rate in tenths of a liter per minute:
	O2 %:
	Titrate to keep O2 Sat Above: 92%
	Indications for O2 therapy: Device 2:
	Device 3:
	PACU & Post-op
[X] Incentive spirometry	Routine, Once, PACU & Post-op
Mechanical ventilation	Routine, PACU & Post-op
•	Mechanical Ventilation:
	Vent Management Strategies:
Consults	
For Physician Consult orders use sidebar	
Conquite Ancilland	
Consults Ancillary	
[] Consult to Case Management for discharge planning	Consult Reason: Discharge Planning PACU & Post-op
[] Consult to Social Work	Reason for Consult: PACU & Post-op
[X] Consult PT Eval and Treat	Reasons for referral to Physical Therapy (mark all applicable):
	Are there any restrictions for positioning or mobility?
	Please provide safe ranges for HR, BP, O2 saturation(if
	values are very abnormal):
	Weight Bearing Status:
	PACU & Post-op

] Consult PT wound care	Special Instructions: Location of Wound?
	PACU & Post-op
X] Consult OT Eval and Teat	Reason for referral to Occupational Therapy (mark all that
	apply):
	Are there any restrictions for positioning or mobility?
	Please provide safe ranges for HR, BP, O2 saturation(if
	values are very abnormal):
	Weight Bearing Status:
	PACU & Post-op
] Consult to Nutrition Services	Reason For Consult?
	Purpose/Topic:
	PACU & Post-op
] Consult to Spiritual Care	Reason for consult?
	PACU & Post-op
Description of the Impulsion of the Impu	Routine, Once
	Reason for consult:
	PACU & Post-op
] Consult to Wound Ostomy Care nurse	Reason for consult:
	Consult for NPWT:
	Reason for consult:
	PACU & Post-op
] Consult to Respiratory Therapy	Reason for Consult?
	PACU & Post-op